In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz International GmbH

Division of Novartis AG
www.sandoz.com

Latest From Sandoz International GmbH

Value Added Medicines Hold Promise Despite Challenges

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

Value-Added Medicines Market Intelligence

Sandoz Beats UK AirFluSal Passing-Off Charge

Sandoz did not pass off its AirFluSal Forspiro combination inhaler as GSK’s Seretide reference brand by adopting livery and packaging in similar colors, the UK’s High Court has determined.

United Kingdom Intellectual Property

Australian Price Cuts Keep On Coming

Lamivudine combinations with zidovudine, as well as ezetimibe, bosentan and infliximab were among the drugs in the crosshairs for Australian reimbursement price cuts from 1 October.

 

Australia Reimbursement

US Biosimilar Market – Who's In It For The Long Haul?

A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?

Commercial Strategy
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register